Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 18, 1998

View Archived Issues

RPR and Oxford BioMedica enter collaboration on gene expression control technology

Millennium delivers two drug targets for screening to Lilly

ArQule enters collaboration with R.W. Johnson for discovery of novel pharmaceuticals

Leukotriene biosynthesis inhibitors described by Ortho-McNeil for inflammatory disorders

Novel antiviral nucleoside analogues from Glaxo Wellcome, U. Michigan

Macrolactam monosaccharide of microbial origin with antifungal and antibacterial activity

Lilly patents novel mGluR modulators

Selective 5-HT1D receptor agonists from MS&D useful for migraine

Chirocaine receives first regulatory approval in Sweden

HMR patents new series of tachykinin receptor antagonists for asthma, cough and bronchitis

Pivotal clinical trials begin for Epic's sustained-release LHRH analogue

Merck broadens cancer research activities by acquiring majority holding in U.S. company

Novel orally active tumor angiogenesis inhibitors licensed by Cell Therapeutics

NIH offers new patented therapy for primary brain tumors for licensing

NIH seeks licensees for michellamine antiviral agents

Techniclone's Rx for B-cell NHL qualifies for orphan designation

Gene discovery collaboration between Bayer and Myriad extended for two more years

U.K. launch for novel antipsychotic agent: zotepine

Boehringer Ingelheim submits U.S. NDA for osteoarthritis treatment

New market release for sildenafil

Collaborative effort at SB and NPS results in development of small-molecule calcilytic

Diatide receives approvable letter for NeoTect

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 6, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Cytospire raises £61M series A to target EGFR in solid tumors
BioWorld
Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance...
Bio Korea 2026: US policy risks shift to execution framework
BioWorld
Regulatory uncertainty that dominated the life science sector in 2025 is transitioning into an execution framework for biotechnology companies, provided companies...
Latus Bio series A financing supports early-stage programs
BioWorld Science
Latus Bio Inc. has closed a $97 million series A financing to support its broad therapeutics pipeline based on novel AAV capsid variants. Proceeds from the...